neuroscience pipeline
Eli Lilly Acquires SiteOne for Up to $1B to Expand Non-Opioid Pain Pipeline
Eli Lilly; SiteOne Therapeutics; non-opioid pain treatment; STC-004; acquisition; Nav1.8 inhibitor; chronic pain; neuroscience pipeline; Vertex; pharmaceutical industry
Johnson & Johnson Discontinues Seltorexant Alzheimer’s Program and Trims Neuroscience Pipeline
Johnson & Johnson, seltorexant, Alzheimer’s disease, neuroscience pipeline, clinical trials, pharmaceutical industry